CGON
Price
$72.61Alerts
Change
-$0.03 (-0.04%)
Updated
Nov 11 closing price
Capitalization
6.74B
Intraday BUY SELL Signals
SRRK
Price
$46.60Alerts
Change
-$1.40 (-2.92%)
Updated
Nov 11 closing price
Capitalization
5.72B
118 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CGON vs SRRK

CGON vs SRRK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CGON vs. SRRK commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGON is a StrongBuy and SRRK is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CGON with price predictions
Nov 10, 2026

CGON in upward trend: price rose above 50-day moving average on November 06, 2026

CGON moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CGON as a result. In 37 of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for CGON just turned positive on October 22, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in 26 of 29 cases over the following month. The odds of a continued upward trend are 90%.

Following a +9.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 118 of 148 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The 10-day RSI Indicator for CGON moved out of overbought territory on November 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In 11 of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

CGON broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CGON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.545) is normal, around the industry mean (3.498). P/E Ratio (-28.249) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for SRRK with price predictions
Nov 10, 2026

SRRK's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SRRK turned positive on October 21, 2026. Looking at past instances where SRRK's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on SRRK as a result. In 72 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

SRRK moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +13.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRRK advanced for three days, in 228 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The 10-day RSI Indicator for SRRK moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 24 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for SRRK moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

SRRK broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SRRK entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SRRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.525) is normal, around the industry mean (3.498). P/E Ratio (-14.181) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
SRRK: Fundamental Ratings
SRRK
OUTLOOK RATING
1..100
32
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
PROFIT vs RISK RATING
1..100
59
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
35
SEASONALITY SCORE
1..100
29

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CGONSRRK
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CGON: $72.64 vs. SRRK: $48.00)
Brand notoriety: CGON and SRRK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGON: 74% vs. SRRK: 103%
Market capitalization -- CGON: $6.74B vs. SRRK: $5.72B
CGON [@Biotechnology] is valued at $6.74B. SRRK’s [@Biotechnology] market capitalization is $5.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGON’s FA Score shows that 1 FA rating(s) are green while SRRK’s FA Score has 0 green FA rating(s).

  • CGON’s FA Score: 1 green, 4 red.
  • SRRK’s FA Score: 0 green, 5 red.
According to our system of comparison, both CGON and SRRK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGON’s TA Score shows that 4 TA indicator(s) are bullish while SRRK’s TA Score has 4 bullish TA indicator(s).

  • CGON’s TA Score: 4 bullish, 5 bearish.
  • SRRK’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CGON is a better buy in the short-term than SRRK.

Price Growth

CGON (@Biotechnology) experienced а +13.39% price change this week, while SRRK (@Biotechnology) price change was +9.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

SRRK is expected to report earnings on Mar 09, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CGON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGON has been loosely correlated with MLTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGON
1D Price
Change %
CGON100%
-2.81%
MLTX - CGON
49%
Loosely correlated
-0.48%
ORKA - CGON
44%
Loosely correlated
+4.72%
SRRK - CGON
43%
Loosely correlated
-6.89%
IDYA - CGON
43%
Loosely correlated
-0.87%
LXEO - CGON
40%
Loosely correlated
-2.55%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SNOY9.300.14
+1.53%
YieldMax SNOW Option Income Strategy ETF (SNOY)
EZJ59.91N/A
N/A
ProShares Ultra MSCI Japan (EZJ)
XLRE44.58-0.06
-0.13%
State Street Real Estate Select Sector SPDR ETF (XLRE)
BSL12.90-0.02
-0.15%
Blackstone Senior Floating Rate 2027 Term Fund
FIIG20.01-0.14
-0.69%
First Trust Intermediate Duration Investment Grade Corporate ETF (FIIG)